Benzylazanium;4-hydroxy-1-[(2-methylpropan-2-yl)oxycarbonyl]piperidine-2-carboxylate

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: Benzylazanium;4-hydroxy-1-[(2-methylpropan-2-yl)oxycarbonyl]piperidine-2-carboxylate
• 英文别名: benzylazanium;4-hydroxy-1-[(2-methylpropan-2-yl)oxycarbonyl]piperidine-2-carboxylate
• 化学式: C18H28N2O5
• 分子量: 352.4
• InChiKey: QMLALKYUTWPCAI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.98
• 重原子数：
  25
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  113
• 氢给体数：
  3
• 氢受体数：
  6

文献信息

• QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS
  申请人：Halsall Christopher Thomas

  公开号：US20110152297A1

  公开（公告）日：2011-06-23

  The invention concerns quinazoline derivatives of the Formula I, or pharmaceutically acceptable salts thereof: wherein each of R 1 , R 2 , R 3 , R 4 and m are as defined in the description; processes for their preparation; pharmaceutical compositions containing them and their use in the manufacture of a medicament for providing an anti-proliferative effect. The quinazoline derivatives of Formula I are expected to be useful in the treatment of diseases such as certain cancers mediated by erbB receptor tyrosine kinases, and, for example, EGFR tyrosine kinase.

  本发明涉及公式I的喹唑啉衍生物或其药学上可接受的盐：其中R1，R2，R3，R4和m的定义如描述中所定义；其制备方法；含有它们的制药组合物以及它们用于制造抗增殖效应药物的用途。公式I的喹唑啉衍生物预计可用于治疗某些由erbB受体酪氨酸激酶介导的癌症，例如EGFR酪氨酸激酶。
• US8735410B2
  申请人：——

  公开号：US8735410B2

  公开（公告）日：2014-05-27